REVIEW article
Front. Immunol.
Sec. Inflammation
This article is part of the Research TopicThe Experimental Models as a Tool for Studying Therapeutic Targets in COPD: Lessons LearnedView all 7 articles
Dynamic Changes of Immune Cells and Therapeutic Responses in Experimental Models of COPD
Provisionally accepted- 1Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
- 2Southwest Medical University, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder characterized by a complex pathogenesis involving chronic inflammation, protease–antiprotease imbalance, oxidative stress, and epigenetic regulation. Experimental models, including cigarette smoke exposure, air pollution, and acute exacerbation models, provide essential platforms for investigating immune cell dynamics during disease initiation and progression. Macrophages contribute to inflammatory amplification and tissue destruction through polarization imbalance and metabolic reprogramming. Neutrophils exacerbate persistent lung injury via recruitment, protease release, NET formation, and delayed apoptosis, while also promoting airway remodeling during the repair phase. T cells—particularly CD8⁺, Th1/Th17, and tissue-resident memory T cells—sustain chronic inflammation through cytotoxicity and cytokine networks, whereas impaired Treg function hinders inflammation resolution. Additional immune populations, such as NK cells, eosinophils, and fibrocytes, further drive inflammatory amplification and fibrotic remodeling. Therapeutic explorations targeting distinct inflammatory phenotypes indicate that conventional glucocorticoids and PDE4 inhibitors remain beneficial in eosinophil-driven inflammation, whereas biologics targeting IL-5, IL-13/IL-4, TSLP, and IL-33 have produced variable outcomes in COPD clinical trials. These findings highlight the importance of precision phenotyping and personalized immunomodulatory strategies. Overall, systematic elucidation of immune cell dynamics in COPD experimental models provides new insights into mechanisms of inflammation persistence and therapeutic responses, offering a theoretical basis for developing targeted interventions.
Keywords: chronic obstructive pulmonary disease1, Experimental Models2, Immune cells3, keyword5, Targeted immunotherapy4
Received: 03 Sep 2025; Accepted: 12 Feb 2026.
Copyright: © 2026 Xie, Li, Du, Li, Li, ZHANG, Zeng, zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jingxian Xie
Yong Yang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
